Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications.



Godman, Brian, Hill, Andrew, Simoens, Steven, Selke, Gisbert, Selke Krulichová, Iva, Zampirolli Dias, Carolina, Martin, Antony P ORCID: 0000-0003-4383-6038, Oortwijn, Wija, Timoney, Angela, Gustafsson, Lars
et al (show 40 more authors) (2021) Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications. Expert review of pharmacoeconomics & outcomes research, 21 (4). pp. 527-540.

[thumbnail of Godman_2021_Cancer-drug-pricing-Europe- Accepted-for-publication.pdf] Text
Godman_2021_Cancer-drug-pricing-Europe- Accepted-for-publication.pdf - Author Accepted Manuscript

Download (386kB) | Preview

Abstract

- CLEAN VERSION <b>Introduction</b>: There are growing concerns among European health authorities regarding increasing prices for new cancer medicines, prices not necessarily linked to health gain and the implications for the sustainability of their healthcare systems. <b>Areas covered</b>: Narrative discussion principally among payers and their advisers regarding potential approaches to the pricing of new cancer medicines. <b>Expert commentary</b>: A number of potential pricing approaches are discussed including minimum effectiveness levels for new cancer medicines, managed entry agreements, multicriteria decision analyses (MCDAs), differential/tiered pricing, fair pricing models, amortization models as well as de-linkage models. We are likely to see a growth in alternative pricing deliberations in view of ongoing challenges including the considerable number of new cancer medicines in development including new gene therapies and being launched with uncertainty regarding their value, continued high prices coupled with the extent of confidential discounts for reimbursement; however, balanced against the need for new cancer medicines. This will lead to greater scrutiny over the prices of patent oncology medicines as more standard medicines lose their patent, calls for greater transparency as well as new models including amortization models. We will be monitoring these developments.

Item Type: Article
Uncontrolled Keywords: Alternative pricing approaches, cancer medicines, europe, managed entry agreements, multicriteria decision analyses, minimum effectiveness criteria, payers, transparent pricing approaches, tiered pricing approaches
Depositing User: Symplectic Admin
Date Deposited: 17 Feb 2021 14:36
Last Modified: 25 Jan 2023 14:13
DOI: 10.1080/14737167.2021.1884546
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3115771